الفهرس 
Pathogenesis of Prostate CancerOnly 14 pages are availabe for public view
 |  | from | 111 |  |  |
| | | from | 111 | | |
Abstract
PC is the most reported male cancer as well as the second leading cause of cancer-related deaths in Western men, excluding non-melanoma skin diseases. Ever since 1941, when it was discovered that lowering testosterone levels via orchiectomy or estrogen injections improved symptoms in patients with metastatic, exogenous hormone naïve disease, ADT(ADT) became the mainstay treatment for locally advanced PC (clinical tumor stages T3–T4, PSA > 20 ng/mL). However, despite reducing testosterone production to castrate levels (≤50 ng/ dL), many patients will relapse and develop castration resistant disease within 2–3 years post treatment, that is often more aggressive, currently incurable and has a poor prognosis with only 16–18 months of survival. PC is one of the commonest cancers diagnosed among males as well as the second leading cause of cancer related deaths in many countries.
In the last decades modalites of management of PC have been changed and also ways of dealing with it due to development of many drugs and interventions in this topic with many controversies.
One of these controversies is the usage of hormonal therapy in management of metastatic PC, monotherapy vs CAB.
In our study we followed up patients with metastatic PC receiving ADT in different forms (orchiectomy, LHRH analogue, orchiectomy plus antiandrogens, LHRH analogue plus antiandrogens) comparing results regarding PSA levels, number of metastases in bone scan, cost effectiveness and QOL.
In conclusion, the results of our study confirmed that there is statistically significant difference in favour of LHRH analogue plus antiandrogens over other modalities.